RituxiRel (Rituximab) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen used in the treatment of non-Hodgkin lymphoma (NHL), blood cancer (Chronic lymphocytic leukemia) and rheumatoid arthritis . RituxiRel is a prescription drug.
Manufacturer : Reliance Life Sciences
Strengths available : 100mg & 500mg
Storage : Store at temperature between 2°C- 8°C
- Do not administer as an intravenous push or bolus.
- Administer only as an intravenous (IV) infusion.
- Premedicate before each infusion with acetaminophen and an antihistamine.
For RA patients, methylprednisolone 100 mg IV or its equivalent is recommended 30 minutes prior to each infusion. Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.
First Infusion: Initiate infusion at a rate of 50 mg/hr. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Subsequent Infusions: Initiate infusion at a rate of 100 mg/hr. In the absence of infusion toxicity, increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr.
Most common side effects are Headache, Weakness, Edema, Infection, Hair loss, Itching, Chills, Febrile neutropenia, Decreased white blood cell count (neutrophils), Infusion reaction.